| Literature DB >> 31758949 |
Nicholas R Larson1, Yangjie Wei1, Indira Prajapati2, Aishik Chakraborty3, Bjorn Peters2, Cavan Kalonia4, Suzanne Hudak4, Sureshkumar Choudhary4, Reza Esfandiary4, Prajna Dhar3, Christian Schöneich2, C Russell Middaugh5.
Abstract
Polysorbates are used ubiquitously in protein therapeutic drugs to help minimize adsorption to surfaces and aggregation. It has been recognized that polysorbate can itself degrade and in turn result in loss of efficacy of therapeutic proteins. We studied the 2 main pathways of polysorbate 80 (PS80) degradation, enzymatic ester hydrolysis, and oxidation. Degraded polysorbates were quantified through mass spectrometry to identify the loss of individual components. Next Langmuir trough adsorption isotherms were used to characterize changes in the surface activity of the degraded polysorbates. PS80 degraded via hydrolysis results in slower surface adsorption rates, whereas the oxidized PS80 show increased surface activity. However, the critical micelle concentration remained unchanged. A monoclonal antibody was formulated with stock and degraded polysorbates to probe their ability to prevent aggregation. Hydrolyzed polysorbate resulted in a large increase in particle formation during shaking stress. Oxidized PS80 was still protective against aggregation for the monoclonal antibody. Monomer loss as measured by SEC was comparable in formulations without PS80 to those with esterase hydrolyzed PS80. Monomer loss for oxidized PS80 was similar to that of nondegraded PS80. Hydrolysis of PS80 resulted in free fatty acids which formed insoluble particles during mechanical agitation which stimulated protein aggregation.Entities:
Keywords: antibody(s); degradation product(s); formulation; lipid(s); protein aggregation; surfactant(s)
Year: 2019 PMID: 31758949 DOI: 10.1016/j.xphs.2019.10.069
Source DB: PubMed Journal: J Pharm Sci ISSN: 0022-3549 Impact factor: 3.534